Compare Novo Nordisk A/S (NVO) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tilray Brands Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Tilray Brands Inc trades at $4.24 (market cap $524.07M). The key difference: Novo Nordisk A/S is far larger — about 420.8× Tilray Brands Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| NVO | TLRY | |
|---|---|---|
Market Cap | $220.53B | $524.07M |
Sector | Health | Health |
52-Week High | $71.70 | $21.00 |
52-Week Low | $35.29 | $4.23 |
Enterprise Value | $239.49B | $621.22M |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
